started · updated
Hanmi Pharm launches Epe, a domestic GLP-1 obesity drug
Hanmi Pharm has officially commenced domestic sales activities for Epe, a GLP-1 receptor agonist obesity treatment. To mark the launch, the company held a large-scale event at the KT Human Resources Development Center in Daejeon, attended by approximately 740 employees from the sustainable growth division.
Epe represents a significant milestone for Hanmi Pharm as it is the first GLP-1 obesity drug where a Korean pharmaceutical company has independently managed the entire process, including candidate discovery, R&D, clinical development, licensing, manufacturing, and commercialization. The drug utilizes Hanmi Pharm’s proprietary Labscovery platform technology.
During the launch event, Hanmi Group Vice Chair Lim Ju-hyun highlighted the product's importance, noting its successful journey from R&D to global technology export and its recent domestic approval in October 2026. The company plans to implement a Total Lifestyle Care (TLS) strategy, which integrates pharmacological treatment with dietary, exercise, and lifestyle management programs to support patients throughout their treatment journey.
Entities
Daejeon · EPE · Hanmi Pharm · Hwang Sang-yeon · Lim Ju-hyun